# A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

> **NCT05321069** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1177 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** BI 1015550
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05321069
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-06
- **Primary completion:** 2024-08-16
- **Final completion:** 2024-12-17
- **Target enrollment:** 1177 (ACTUAL)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05321069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05321069, "A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05321069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*